Serina Therapeutics, Inc. (SER)
NYSEAMERICAN: SER · Real-Time Price · USD
2.780
+0.110 (4.12%)
Aug 11, 2026, 4:00 PM EDT - Market closed
Serina Therapeutics Revenue
Serina Therapeutics had revenue of $130.00K in the twelve months ending March 31, 2026. In the year 2025, Serina Therapeutics had annual revenue of $130.00K with 132.14% growth.
Revenue (ttm)
$130.00K
Revenue Growth
+132.14%
P/S Ratio
320.72
Revenue / Employee
$8,125
Employees
16
Market Cap
41.69M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 130.00K | 74.00K | 132.14% |
| Dec 31, 2024 | 56.00K | -3.10M | -98.22% |
| Dec 31, 2023 | 3.15M | 3.12M | 9,173.53% |
| Dec 31, 2022 | 34.00K | -110.00K | -76.39% |
| Dec 31, 2021 | 144.00K | -217.00K | -60.11% |
| Dec 31, 2020 | 361.00K | -1.37M | -79.11% |
| Dec 31, 2019 | 1.73M | 332.00K | 23.78% |
| Dec 31, 2018 | 1.40M | -8.00K | -0.57% |
| Dec 31, 2017 | 1.40M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 31.52M |
| Veru Inc. | 16.89M |
| Radiopharm Theranostics | 10.86M |
| Apollomics | 8.84M |
| Dyadic International | 3.81M |
| BeyondSpring | 1.88M |
| Nutriband | 1.80M |
| CervoMed | 331.30K |
SER News
- 18 days ago - Serina Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - GlobeNewsWire
- 19 days ago - Serina Therapeutics completes enrollment and dosing in Parkinson’s trial - TheFly
- 19 days ago - Serina Therapeutics Announces Completion of Enrollment and Dosing in Cohort 1 of Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 20 days ago - Serina Therapeutics appoints Trevi Therapeutics CCO Farrell Simon to board - TheFly
- 20 days ago - Serina Therapeutics Appoints Farrell Simon to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Serina completes sentinel dosing in Cohort 1 of Phase 1b trial of SER-252 - TheFly
- 4 weeks ago - Serina Therapeutics Announces Completion of Sentinel Dosing in Cohort 1 of Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease - GlobeNewsWire
- 5 weeks ago - Serina Therapeutics initiated with a Buy at BTIG - TheFly